Atossa Therapeutics, Inc.
ATOSHealthcare|Biotechnology|US
$2.12
+0.10 (+4.95%)
DCF Value
$4.35
Tangible Book / Share
$3.01
Cash / Share
$2.93
Financials
Financial Snapshot
Market Cap
$21.2M
Enterprise Value
-$4.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$37.7M
Cash & Investments
$26.1M
Net Cash
$26.1M
Free Cash Flow (TTM)
-$35.8M
Operating CF (TTM)
-$35.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$26.1M
Quarterly Burn
$8.9M
Monthly Burn
$3.0M
Est. Runway
~2.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.0M | $7.2M | $10.4M | $12.7M | $39.7M | $136.4M | $110.9M | $88.5M | $71.1M | $41.3M | $26.1M | |
| Operating Cash Flow | -$5.4M | -$6.6M | -$9.0M | -$9.1M | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M | -$35.8M | |
| Free Cash Flow | -$5.4M | -$6.6M | -$9.1M | -$9.1M | -$11.6M | -$16.5M | -$20.8M | -$21.0M | -$21.0M | -$29.8M | -$35.8M | |
| Capital Expenditure | -$9.2K | $0.00 | -$110.9K | -$7.6K | -$9.4K | -$9.0K | -$27.0K | -$14.0K | -$19.0K | -$23.0K | -$14.0K | |
| Financing Cash Flow | $4.7M | $10.8M | $12.3M | $11.3M | $38.6M | $113.3M | $0.00 | -$1.5M | $3.7M | $0.00 | $4.0M |
R&D Spending
R&D (TTM)
$21.2M
R&D Intensity
—
R&D Growth vs Prior
+0.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $770.4K | $2.3M | $4.2M | $7.1M | $6.6M | $9.2M | $15.1M | $17.3M | $14.1M | $21.2M | $21.2M | |
| SG&A | $6.5M | $4.9M | $7.2M | $10.6M | $8.0M | $11.3M | $12.6M | $14.0M | $13.5M | $16.0M | $18.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $303.5K | $129.0K | $44.2K | $52.8K | $46.6K | $23.0K | $8.0K | $23.0K | $17.0K | $0.00 | $8.0K | |
| Gross Profit | -$303.5K | -$129.0K | -$44.2K | -$52.8K | -$46.6K | -$23.0K | -$8.0K | -$23.0K | -$17.0K | $0.00 | -$8.0K | |
| R&D | $770.4K | $2.3M | $4.2M | $7.1M | $6.6M | $9.2M | $15.1M | $17.3M | $14.1M | $21.2M | $21.2M | |
| SG&A | $6.5M | $4.9M | $7.2M | $10.6M | $8.0M | $11.3M | $12.6M | $14.0M | $13.5M | $16.0M | $18.0M | |
| Operating Income | -$7.2M | -$7.2M | -$11.4M | -$17.3M | -$14.6M | -$20.5M | -$27.7M | -$31.4M | -$27.6M | -$37.1M | -$39.3M | |
| Interest Expense | $0.00 | $192.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$6.4M | -$8.1M | -$11.4M | -$17.2M | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M | -$37.7M | |
| Net Income | -$6.4M | -$8.1M | -$11.4M | -$17.2M | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M | -$37.7M | |
| EPS (Diluted) | -388.95 | -164.55 | -82.50 | -30.45 | -29.55 | -2.70 | -3.15 | -3.60 | -3.00 | -4.04 | -4.34 | |
| EBITDA | -$6.1M | -$7.8M | -$11.4M | -$17.2M | -$14.6M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M | -$37.7M | |
| Shares Out. (M) | 0.02 | 0.06 | 0.28 | 0.57 | 0.75 | 7.80 | 8.44 | 8.41 | 8.39 | 8.61 | 8.91 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.0M | $7.2M | $10.4M | $12.7M | $39.7M | $136.4M | $110.9M | $88.5M | $71.1M | $41.3M | $26.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $3.3M | $7.9M | $11.5M | $14.3M | $42.8M | $141.2M | $118.2M | $92.2M | $74.5M | $45.6M | $31.0M | |
| Total Assets | $4.1M | $8.2M | $11.7M | $14.5M | $42.8M | $141.3M | $123.5M | $96.3M | $76.4M | $47.6M | $32.3M | |
| Total Current Liabilities | $1.0M | $1.2M | $2.9M | $1.3M | $15.7M | $3.1M | $5.6M | $5.2M | $5.0M | $8.3M | $5.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.0M | $1.2M | $2.9M | $1.3M | $15.7M | $3.1M | $5.6M | $5.2M | $5.0M | $8.3M | $5.5M | |
| Stockholders' Equity | $3.1M | $6.9M | $8.8M | $13.2M | $27.2M | $138.1M | $118.0M | $91.0M | $71.5M | $39.4M | $26.8M | |
| Retained Earnings | -$57.3M | -$65.4M | -$76.8M | -$94.1M | -$111.9M | -$129.2M | -$156.2M | -$186.3M | -$211.8M | -$246.6M | -$264.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.4M | -$6.6M | -$9.0M | -$9.1M | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M | -$35.8M | |
| Capital Expenditure | -$9.2K | $0.00 | -$110.9K | -$7.6K | -$9.4K | -$9.0K | -$27.0K | -$14.0K | -$19.0K | -$23.0K | -$14.0K | |
| Free Cash Flow | -$5.4M | -$6.6M | -$9.1M | -$9.1M | -$11.6M | -$16.5M | -$20.8M | -$21.0M | -$21.0M | -$29.8M | -$35.8M | |
| Investing Cash Flow | -$9.2K | $0.00 | -$110.9K | -$7.6K | -$9.4K | -$9.0K | -$4.7M | -$14.0K | -$19.0K | -$23.0K | -$14.0K | |
| Financing Cash Flow | $4.7M | $10.8M | $12.3M | $11.3M | $38.6M | $113.3M | $0.00 | -$1.5M | $3.7M | $0.00 | $4.0M | |
| Issuance of Stock | $4.7M | $10.0M | $12.3M | $11.3M | $33.6M | $69.7M | $0.00 | $0.00 | $3.7M | $0.00 | $4.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.5M | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $876.2K | $786.5K | $2.5M | $8.8M | $3.0M | $5.3M | $6.8M | $4.6M | $2.3M | $2.6M | $2.8M | |
| Net Change in Cash | -$687.9K | $4.2M | $3.2M | $2.2M | $27.0M | $96.8M | -$25.5M | -$22.4M | -$17.4M | -$29.8M | -$31.8M |
Dilution Tracker
Shares outstanding grew 1042.2% over 5 years — significant dilution
Shares Outstanding
10M
5-Year Share Growth
+1042.2%
Stock Issuance (TTM)
$4.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.02 | 0.06 | 0.28 | 0.57 | 0.75 | 7.80 | 8.44 | 8.41 | 8.39 | 8.61 | 8.91 | |
| Change vs Prior % | — | 296.9% | 326.5% | 104.4% | 33.1% | 934.2% | 8.3% | -0.4% | -0.2% | 2.6% | 3.5% | |
| Stock Issuance | $4.7M | $10.0M | $12.3M | $11.3M | $33.6M | $69.7M | $0.00 | $0.00 | $3.7M | $0.00 | $4.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.5M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $876.2K | $786.5K | $2.5M | $8.8M | $3.0M | $5.3M | $6.8M | $4.6M | $2.3M | $2.6M | $2.8M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -205.6% | -117.1% | -129.5% | -131.0% | -65.6% | -14.9% | -22.9% | -33.1% | -35.7% | -88.4% | -103.0% | |
| ROA % | -153.7% | -99.5% | -97.3% | -118.9% | -41.6% | -14.6% | -21.8% | -31.3% | -33.4% | -73.0% | -116.8% | |
| ROIC % | -234.1% | -103.6% | -129.5% | -130.6% | -53.7% | -14.9% | -23.5% | -34.5% | -38.6% | -94.4% | -146.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -132.3% | 57.5% | 65.7% | -19.4% | 11.7% | 50.6% | 65.2% | -187.5% | 26.1% | 100.0% | |
| Operating Income | 43.2% | 0.9% | -59.1% | -51.0% | 15.4% | -40.5% | -34.9% | -13.3% | 12.0% | -34.5% | |
| Net Income | 59.6% | -27.5% | -40.4% | -51.2% | -3.4% | -15.6% | -30.8% | -11.6% | 15.3% | -36.3% | |
| EPS (Diluted) | 72.9% | 57.7% | 49.9% | 63.1% | 3.0% | 90.9% | -16.7% | -14.3% | 16.7% | -34.7% | |
| Operating Cash Flow | 61.5% | -22.7% | -35.9% | -1.9% | -26.7% | -42.4% | -26.0% | -0.9% | -0.4% | -41.5% | |
| Free Cash Flow | 61.8% | -22.5% | -37.6% | -0.7% | -26.7% | -42.3% | -26.1% | -0.8% | -0.4% | -41.5% | |
| R&D Expense | -67.3% | 202.2% | 80.8% | 69.4% | -7.3% | 39.4% | 63.8% | 14.9% | -18.6% | 50.1% | |
| SG&A Expense | -36.9% | -25.0% | 48.7% | 47.0% | -24.7% | 41.4% | 11.5% | 11.4% | -3.8% | 18.2% | |
| Total Assets | -33.6% | 97.0% | 43.6% | 23.7% | 195.5% | 229.7% | -12.6% | -22.1% | -20.6% | -37.7% | |
| Book Value / Share | -46.8% | -43.6% | -70.2% | -26.9% | 55.2% | -50.8% | -21.1% | -22.5% | -21.3% | -46.4% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -64.2% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 55.5% | 296.9% | 326.5% | 104.4% | 33.1% | 934.2% | 8.3% | -0.4% | -0.2% | 2.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.70
10Y Low / Med / High0.40 / 1.22 / 1.94
EV/EBITDA0.13
10Y Low / Med / High0.54 / 1.62 / 1.99
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.35
Tangible Book / Share
$3.01
Net Current Assets / Share
$2.56
Graham Net-Net
$2.32
Cash / Share
$2.93
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.65 | -0.28 | -0.19 | -0.77 | -0.48 | -8.89 | -2.52 | -3.67 | -4.72 | -2.19 | -0.49 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.34 | 0.44 | 0.48 | 1.01 | 0.40 | 1.35 | 0.57 | 1.22 | 1.66 | 1.94 | 0.70 | |
| EV/EBITDA | -0.19 | 0.54 | 0.54 | -0.04 | 1.99 | -2.47 | 1.62 | -0.75 | -1.87 | -1.00 | 0.13 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-12.05
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $54.5M | $82.4M | $118.7M |
| Net Income | -$33.0M | -$24.2M | $47.5M |
| EPS | $-3.75 | $-2.78 | $2.71 |
| # Analysts (EPS) | 2 | 2 | 2 |